Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Stock Competitors & Peer Comparison
See (KNSA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| KNSA | $45.78 | -0.63% | 3.4B | 61.04 | $0.75 | N/A |
| VRTX | $469.34 | -1.84% | 119.2B | 31.04 | $15.12 | N/A |
| REGN | $745.77 | -0.11% | 77.5B | 18.00 | $41.44 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $700.45 | -1.19% | 43.3B | 35.76 | $19.59 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $313.41 | -1.20% | 41.6B | 135.68 | $2.31 | N/A |
| INSM | $139.50 | -0.01% | 30.1B | -21.73 | -$6.42 | N/A |
| UTHR | $536.12 | +0.62% | 23.5B | 19.26 | $27.83 | N/A |
| BNTX | $91.19 | +1.21% | 22.9B | -32.80 | -$2.78 | N/A |
Stock Comparison
KNSA vs VRTX Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, VRTX has a market cap of 119.2B. Regarding current trading prices, KNSA is priced at $45.78, while VRTX trades at $469.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas VRTX's P/E ratio is 31.04. In terms of profitability, KNSA's ROE is +0.11%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, KNSA is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check VRTX's competition here
KNSA vs REGN Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, REGN has a market cap of 77.5B. Regarding current trading prices, KNSA is priced at $45.78, while REGN trades at $745.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas REGN's P/E ratio is 18.00. In terms of profitability, KNSA's ROE is +0.11%, compared to REGN's ROE of +0.15%. Regarding short-term risk, KNSA is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check REGN's competition here
KNSA vs VRNA Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, KNSA is priced at $45.78, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas VRNA's P/E ratio is -102.80. In terms of profitability, KNSA's ROE is +0.11%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, KNSA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check VRNA's competition here
KNSA vs ARGX Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, ARGX has a market cap of 43.3B. Regarding current trading prices, KNSA is priced at $45.78, while ARGX trades at $700.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas ARGX's P/E ratio is 35.76. In terms of profitability, KNSA's ROE is +0.11%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, KNSA is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check ARGX's competition here
KNSA vs SGEN Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, KNSA is priced at $45.78, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas SGEN's P/E ratio is -57.19. In terms of profitability, KNSA's ROE is +0.11%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, KNSA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check SGEN's competition here
KNSA vs ALNY Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, ALNY has a market cap of 41.6B. Regarding current trading prices, KNSA is priced at $45.78, while ALNY trades at $313.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas ALNY's P/E ratio is 135.68. In terms of profitability, KNSA's ROE is +0.11%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, KNSA is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check ALNY's competition here
KNSA vs INSM Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, INSM has a market cap of 30.1B. Regarding current trading prices, KNSA is priced at $45.78, while INSM trades at $139.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas INSM's P/E ratio is -21.73. In terms of profitability, KNSA's ROE is +0.11%, compared to INSM's ROE of -1.68%. Regarding short-term risk, KNSA is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check INSM's competition here
KNSA vs UTHR Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, UTHR has a market cap of 23.5B. Regarding current trading prices, KNSA is priced at $45.78, while UTHR trades at $536.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas UTHR's P/E ratio is 19.26. In terms of profitability, KNSA's ROE is +0.11%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, KNSA is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check UTHR's competition here
KNSA vs BNTX Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, KNSA is priced at $45.78, while BNTX trades at $91.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas BNTX's P/E ratio is -32.80. In terms of profitability, KNSA's ROE is +0.11%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, KNSA is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check BNTX's competition here
KNSA vs MRNA Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, MRNA has a market cap of 20.8B. Regarding current trading prices, KNSA is priced at $45.78, while MRNA trades at $52.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas MRNA's P/E ratio is -7.24. In terms of profitability, KNSA's ROE is +0.11%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, KNSA is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check MRNA's competition here
KNSA vs BGNE Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, KNSA is priced at $45.78, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas BGNE's P/E ratio is -22.55. In terms of profitability, KNSA's ROE is +0.11%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, KNSA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check BGNE's competition here
KNSA vs ROIV Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, ROIV has a market cap of 20.1B. Regarding current trading prices, KNSA is priced at $45.78, while ROIV trades at $28.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas ROIV's P/E ratio is -23.98. In terms of profitability, KNSA's ROE is +0.11%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, KNSA is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check ROIV's competition here
KNSA vs RPRX Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, RPRX has a market cap of 19.6B. Regarding current trading prices, KNSA is priced at $45.78, while RPRX trades at $45.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas RPRX's P/E ratio is 25.65. In terms of profitability, KNSA's ROE is +0.11%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, KNSA is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check RPRX's competition here
KNSA vs RVMD Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, RVMD has a market cap of 18.8B. Regarding current trading prices, KNSA is priced at $45.78, while RVMD trades at $94.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas RVMD's P/E ratio is -15.94. In terms of profitability, KNSA's ROE is +0.11%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, KNSA is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check RVMD's competition here
KNSA vs DNA-WT Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, KNSA is priced at $45.78, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.11%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, KNSA is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check DNA-WT's competition here
KNSA vs INCY Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, INCY has a market cap of 18.4B. Regarding current trading prices, KNSA is priced at $45.78, while INCY trades at $92.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas INCY's P/E ratio is 14.64. In terms of profitability, KNSA's ROE is +0.11%, compared to INCY's ROE of +0.29%. Regarding short-term risk, KNSA is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check INCY's competition here
KNSA vs GMAB Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, GMAB has a market cap of 16.1B. Regarding current trading prices, KNSA is priced at $45.78, while GMAB trades at $26.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas GMAB's P/E ratio is 16.97. In terms of profitability, KNSA's ROE is +0.11%, compared to GMAB's ROE of +0.11%. Regarding short-term risk, KNSA is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check GMAB's competition here
KNSA vs ASND Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, ASND has a market cap of 13.9B. Regarding current trading prices, KNSA is priced at $45.78, while ASND trades at $225.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas ASND's P/E ratio is -51.71. In terms of profitability, KNSA's ROE is +0.11%, compared to ASND's ROE of +1.28%. Regarding short-term risk, KNSA is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check ASND's competition here
KNSA vs BBIO Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, BBIO has a market cap of 13.5B. Regarding current trading prices, KNSA is priced at $45.78, while BBIO trades at $69.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas BBIO's P/E ratio is -18.36. In terms of profitability, KNSA's ROE is +0.11%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, KNSA is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check BBIO's competition here
KNSA vs KRTX Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, KNSA is priced at $45.78, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas KRTX's P/E ratio is -28.09. In terms of profitability, KNSA's ROE is +0.11%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, KNSA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check KRTX's competition here
KNSA vs SMMT Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, SMMT has a market cap of 12B. Regarding current trading prices, KNSA is priced at $45.78, while SMMT trades at $16.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas SMMT's P/E ratio is -11.19. In terms of profitability, KNSA's ROE is +0.11%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, KNSA is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check SMMT's competition here
KNSA vs IONS Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, IONS has a market cap of 11.8B. Regarding current trading prices, KNSA is priced at $45.78, while IONS trades at $71.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas IONS's P/E ratio is -29.91. In terms of profitability, KNSA's ROE is +0.11%, compared to IONS's ROE of -0.69%. Regarding short-term risk, KNSA is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check IONS's competition here
KNSA vs RNAM Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, KNSA is priced at $45.78, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas RNAM's P/E ratio is -17.39. In terms of profitability, KNSA's ROE is +0.11%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, KNSA is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check RNAM's competition here
KNSA vs BMRN Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, BMRN has a market cap of 11.3B. Regarding current trading prices, KNSA is priced at $45.78, while BMRN trades at $58.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas BMRN's P/E ratio is 32.51. In terms of profitability, KNSA's ROE is +0.11%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, KNSA is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check BMRN's competition here
KNSA vs EXEL Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, EXEL has a market cap of 11.1B. Regarding current trading prices, KNSA is priced at $45.78, while EXEL trades at $41.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas EXEL's P/E ratio is 14.68. In terms of profitability, KNSA's ROE is +0.11%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, KNSA is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check EXEL's competition here
KNSA vs JAZZ Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, JAZZ has a market cap of 11B. Regarding current trading prices, KNSA is priced at $45.78, while JAZZ trades at $178.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas JAZZ's P/E ratio is -30.57. In terms of profitability, KNSA's ROE is +0.11%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, KNSA is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check JAZZ's competition here
KNSA vs MDGL Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, MDGL has a market cap of 10.1B. Regarding current trading prices, KNSA is priced at $45.78, while MDGL trades at $444.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas MDGL's P/E ratio is -34.62. In terms of profitability, KNSA's ROE is +0.11%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, KNSA is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check MDGL's competition here
KNSA vs RXDX Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, KNSA is priced at $45.78, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas RXDX's P/E ratio is -56.47. In terms of profitability, KNSA's ROE is +0.11%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, KNSA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check RXDX's competition here
KNSA vs IMGN Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, KNSA is priced at $45.78, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas IMGN's P/E ratio is -111.55. In terms of profitability, KNSA's ROE is +0.11%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, KNSA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check IMGN's competition here
KNSA vs IBRX Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, IBRX has a market cap of 8.6B. Regarding current trading prices, KNSA is priced at $45.78, while IBRX trades at $8.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas IBRX's P/E ratio is -22.08. In terms of profitability, KNSA's ROE is +0.11%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, KNSA is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check IBRX's competition here
KNSA vs BPMC Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, KNSA is priced at $45.78, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas BPMC's P/E ratio is -51.58. In terms of profitability, KNSA's ROE is +0.11%, compared to BPMC's ROE of -0.33%. Regarding short-term risk, KNSA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check BPMC's competition here
KNSA vs CERE Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, KNSA is priced at $45.78, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas CERE's P/E ratio is -16.47. In terms of profitability, KNSA's ROE is +0.11%, compared to CERE's ROE of -0.72%. Regarding short-term risk, KNSA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check CERE's competition here
KNSA vs AXSM Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, AXSM has a market cap of 8B. Regarding current trading prices, KNSA is priced at $45.78, while AXSM trades at $156.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas AXSM's P/E ratio is -42.41. In terms of profitability, KNSA's ROE is +0.11%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, KNSA is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check AXSM's competition here
KNSA vs TECH Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, TECH has a market cap of 8B. Regarding current trading prices, KNSA is priced at $45.78, while TECH trades at $50.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas TECH's P/E ratio is 95.94. In terms of profitability, KNSA's ROE is +0.11%, compared to TECH's ROE of +0.04%. Regarding short-term risk, KNSA is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check TECH's competition here
KNSA vs PCVX Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, PCVX has a market cap of 7.9B. Regarding current trading prices, KNSA is priced at $45.78, while PCVX trades at $54.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas PCVX's P/E ratio is -9.69. In terms of profitability, KNSA's ROE is +0.11%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, KNSA is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check PCVX's competition here
KNSA vs ARWR Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, ARWR has a market cap of 7.7B. Regarding current trading prices, KNSA is priced at $45.78, while ARWR trades at $55.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas ARWR's P/E ratio is 34.41. In terms of profitability, KNSA's ROE is +0.11%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, KNSA is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check ARWR's competition here
KNSA vs ABVX Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, ABVX has a market cap of 7.6B. Regarding current trading prices, KNSA is priced at $45.78, while ABVX trades at $115.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas ABVX's P/E ratio is -22.38. In terms of profitability, KNSA's ROE is +0.11%, compared to ABVX's ROE of +50.78%. Regarding short-term risk, KNSA is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check ABVX's competition here
KNSA vs HALO Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, HALO has a market cap of 7.5B. Regarding current trading prices, KNSA is priced at $45.78, while HALO trades at $63.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas HALO's P/E ratio is 24.87. In terms of profitability, KNSA's ROE is +0.11%, compared to HALO's ROE of +0.93%. Regarding short-term risk, KNSA is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check HALO's competition here
KNSA vs MTSR Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, KNSA is priced at $45.78, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas MTSR's P/E ratio is -23.58. In terms of profitability, KNSA's ROE is +0.11%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, KNSA is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check MTSR's competition here
KNSA vs CYTK Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, CYTK has a market cap of 7.4B. Regarding current trading prices, KNSA is priced at $45.78, while CYTK trades at $60.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas CYTK's P/E ratio is -9.18. In terms of profitability, KNSA's ROE is +0.11%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, KNSA is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check CYTK's competition here
KNSA vs KRYS Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, KRYS has a market cap of 7.2B. Regarding current trading prices, KNSA is priced at $45.78, while KRYS trades at $247.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas KRYS's P/E ratio is 36.20. In terms of profitability, KNSA's ROE is +0.11%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, KNSA is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check KRYS's competition here
KNSA vs NUVL Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, NUVL has a market cap of 7.2B. Regarding current trading prices, KNSA is priced at $45.78, while NUVL trades at $97.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas NUVL's P/E ratio is -16.74. In terms of profitability, KNSA's ROE is +0.11%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, KNSA is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check NUVL's competition here
KNSA vs MRUS Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, KNSA is priced at $45.78, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas MRUS's P/E ratio is -17.05. In terms of profitability, KNSA's ROE is +0.11%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, KNSA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check MRUS's competition here
KNSA vs ACLX Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, KNSA is priced at $45.78, while ACLX trades at $114.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas ACLX's P/E ratio is -28.11. In terms of profitability, KNSA's ROE is +0.11%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, KNSA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check ACLX's competition here
KNSA vs RETA Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, KNSA is priced at $45.78, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas RETA's P/E ratio is -66.29. In terms of profitability, KNSA's ROE is +0.11%, compared to RETA's ROE of +0.47%. Regarding short-term risk, KNSA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check RETA's competition here
KNSA vs BLTE Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, BLTE has a market cap of 6.5B. Regarding current trading prices, KNSA is priced at $45.78, while BLTE trades at $164.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas BLTE's P/E ratio is -71.04. In terms of profitability, KNSA's ROE is +0.11%, compared to BLTE's ROE of -0.43%. Regarding short-term risk, KNSA is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check BLTE's competition here
KNSA vs KYMR Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, KYMR has a market cap of 6.5B. Regarding current trading prices, KNSA is priced at $45.78, while KYMR trades at $79.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas KYMR's P/E ratio is -21.42. In terms of profitability, KNSA's ROE is +0.11%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, KNSA is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check KYMR's competition here
KNSA vs PRAX Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, PRAX has a market cap of 6.2B. Regarding current trading prices, KNSA is priced at $45.78, while PRAX trades at $293.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas PRAX's P/E ratio is -21.81. In terms of profitability, KNSA's ROE is +0.11%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, KNSA is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check PRAX's competition here
KNSA vs RYTM Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, RYTM has a market cap of 6B. Regarding current trading prices, KNSA is priced at $45.78, while RYTM trades at $87.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas RYTM's P/E ratio is -28.10. In terms of profitability, KNSA's ROE is +0.11%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, KNSA is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check RYTM's competition here
KNSA vs PTGX Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, PTGX has a market cap of 5.9B. Regarding current trading prices, KNSA is priced at $45.78, while PTGX trades at $92.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas PTGX's P/E ratio is -45.05. In terms of profitability, KNSA's ROE is +0.11%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, KNSA is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check PTGX's competition here
KNSA vs CDTX Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, KNSA is priced at $45.78, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas CDTX's P/E ratio is -19.77. In terms of profitability, KNSA's ROE is +0.11%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, KNSA is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check CDTX's competition here
KNSA vs ABCM Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, KNSA is priced at $45.78, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, KNSA's ROE is +0.11%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, KNSA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check ABCM's competition here
KNSA vs COGT Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, COGT has a market cap of 5.5B. Regarding current trading prices, KNSA is priced at $45.78, while COGT trades at $34.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas COGT's P/E ratio is -15.74. In terms of profitability, KNSA's ROE is +0.11%, compared to COGT's ROE of -1.00%. Regarding short-term risk, KNSA is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check COGT's competition here
KNSA vs ISEE Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, KNSA is priced at $45.78, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas ISEE's P/E ratio is -22.44. In terms of profitability, KNSA's ROE is +0.11%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, KNSA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check ISEE's competition here
KNSA vs CGON Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, CGON has a market cap of 5.4B. Regarding current trading prices, KNSA is priced at $45.78, while CGON trades at $64.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas CGON's P/E ratio is -30.91. In terms of profitability, KNSA's ROE is +0.11%, compared to CGON's ROE of -0.23%. Regarding short-term risk, KNSA is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check CGON's competition here
KNSA vs PTCT Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, PTCT has a market cap of 5.3B. Regarding current trading prices, KNSA is priced at $45.78, while PTCT trades at $64.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas PTCT's P/E ratio is 7.52. In terms of profitability, KNSA's ROE is +0.11%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, KNSA is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check PTCT's competition here
KNSA vs CELC Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, CELC has a market cap of 5.3B. Regarding current trading prices, KNSA is priced at $45.78, while CELC trades at $114.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas CELC's P/E ratio is -31.04. In terms of profitability, KNSA's ROE is +0.11%, compared to CELC's ROE of -1.79%. Regarding short-term risk, KNSA is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check CELC's competition here
KNSA vs FBIOX Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, KNSA is priced at $45.78, while FBIOX trades at $24.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas FBIOX's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.11%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, KNSA is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check FBIOX's competition here
KNSA vs CAI Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, CAI has a market cap of 5.1B. Regarding current trading prices, KNSA is priced at $45.78, while CAI trades at $18.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas CAI's P/E ratio is -5.64. In terms of profitability, KNSA's ROE is +0.11%, compared to CAI's ROE of +0.25%. Regarding short-term risk, KNSA is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check CAI's competition here
KNSA vs IMVT Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, IMVT has a market cap of 5B. Regarding current trading prices, KNSA is priced at $45.78, while IMVT trades at $24.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas IMVT's P/E ratio is -9.14. In terms of profitability, KNSA's ROE is +0.11%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, KNSA is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check IMVT's competition here
KNSA vs CRSP Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, CRSP has a market cap of 4.7B. Regarding current trading prices, KNSA is priced at $45.78, while CRSP trades at $48.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas CRSP's P/E ratio is -7.97. In terms of profitability, KNSA's ROE is +0.11%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, KNSA is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check CRSP's competition here
KNSA vs ALKS Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, ALKS has a market cap of 4.6B. Regarding current trading prices, KNSA is priced at $45.78, while ALKS trades at $27.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas ALKS's P/E ratio is 19.41. In terms of profitability, KNSA's ROE is +0.11%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, KNSA is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check ALKS's competition here
KNSA vs XENE Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, XENE has a market cap of 4.6B. Regarding current trading prices, KNSA is priced at $45.78, while XENE trades at $55.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas XENE's P/E ratio is -12.67. In terms of profitability, KNSA's ROE is +0.11%, compared to XENE's ROE of -0.56%. Regarding short-term risk, KNSA is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check XENE's competition here
KNSA vs MIRM Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, MIRM has a market cap of 4.6B. Regarding current trading prices, KNSA is priced at $45.78, while MIRM trades at $90.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas MIRM's P/E ratio is -192.89. In terms of profitability, KNSA's ROE is +0.11%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, KNSA is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check MIRM's competition here
KNSA vs FOLD Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, KNSA is priced at $45.78, while FOLD trades at $14.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas FOLD's P/E ratio is -159.67. In terms of profitability, KNSA's ROE is +0.11%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, KNSA is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check FOLD's competition here
KNSA vs AKRO Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, KNSA is priced at $45.78, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas AKRO's P/E ratio is -14.57. In terms of profitability, KNSA's ROE is +0.11%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, KNSA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check AKRO's competition here
KNSA vs TGTX Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, TGTX has a market cap of 4.5B. Regarding current trading prices, KNSA is priced at $45.78, while TGTX trades at $27.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas TGTX's P/E ratio is 10.09. In terms of profitability, KNSA's ROE is +0.11%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, KNSA is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check TGTX's competition here
KNSA vs ALPN Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, KNSA is priced at $45.78, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas ALPN's P/E ratio is -101.52. In terms of profitability, KNSA's ROE is +0.11%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, KNSA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check ALPN's competition here
KNSA vs OPT Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, KNSA is priced at $45.78, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas OPT's P/E ratio is -1.52. In terms of profitability, KNSA's ROE is +0.11%, compared to OPT's ROE of +0.88%. Regarding short-term risk, KNSA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check OPT's competition here
KNSA vs ERAS Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, ERAS has a market cap of 4.2B. Regarding current trading prices, KNSA is priced at $45.78, while ERAS trades at $13.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas ERAS's P/E ratio is -31.67. In terms of profitability, KNSA's ROE is +0.11%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, KNSA is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check ERAS's competition here
KNSA vs TERN Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, TERN has a market cap of 4.2B. Regarding current trading prices, KNSA is priced at $45.78, while TERN trades at $46.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas TERN's P/E ratio is -45.61. In terms of profitability, KNSA's ROE is +0.11%, compared to TERN's ROE of -0.30%. Regarding short-term risk, KNSA is less volatile compared to TERN. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check TERN's competition here
KNSA vs MRTX Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, KNSA is priced at $45.78, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas MRTX's P/E ratio is -4.82. In terms of profitability, KNSA's ROE is +0.11%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, KNSA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check MRTX's competition here
KNSA vs VKTX Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, VKTX has a market cap of 4.1B. Regarding current trading prices, KNSA is priced at $45.78, while VKTX trades at $35.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas VKTX's P/E ratio is -11.17. In terms of profitability, KNSA's ROE is +0.11%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, KNSA is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check VKTX's competition here
KNSA vs SRRK Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, SRRK has a market cap of 4.1B. Regarding current trading prices, KNSA is priced at $45.78, while SRRK trades at $40.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas SRRK's P/E ratio is -12.16. In terms of profitability, KNSA's ROE is +0.11%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, KNSA is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check SRRK's competition here
KNSA vs LGND Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, LGND has a market cap of 4B. Regarding current trading prices, KNSA is priced at $45.78, while LGND trades at $202.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas LGND's P/E ratio is 33.10. In terms of profitability, KNSA's ROE is +0.11%, compared to LGND's ROE of +0.14%. Regarding short-term risk, KNSA is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check LGND's competition here
KNSA vs APGE Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, APGE has a market cap of 4B. Regarding current trading prices, KNSA is priced at $45.78, while APGE trades at $71.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas APGE's P/E ratio is -17.04. In terms of profitability, KNSA's ROE is +0.11%, compared to APGE's ROE of -0.37%. Regarding short-term risk, KNSA is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check APGE's competition here
KNSA vs CRNX Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, CRNX has a market cap of 3.9B. Regarding current trading prices, KNSA is priced at $45.78, while CRNX trades at $37.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas CRNX's P/E ratio is -7.57. In terms of profitability, KNSA's ROE is +0.11%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, KNSA is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check CRNX's competition here
KNSA vs RYZB Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, KNSA is priced at $45.78, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas RYZB's P/E ratio is -57.86. In terms of profitability, KNSA's ROE is +0.11%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, KNSA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check RYZB's competition here
KNSA vs CBAY Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, KNSA is priced at $45.78, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas CBAY's P/E ratio is -32.81. In terms of profitability, KNSA's ROE is +0.11%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, KNSA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check CBAY's competition here
KNSA vs ADMA Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, ADMA has a market cap of 3.6B. Regarding current trading prices, KNSA is priced at $45.78, while ADMA trades at $15.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas ADMA's P/E ratio is 25.25. In terms of profitability, KNSA's ROE is +0.11%, compared to ADMA's ROE of +0.35%. Regarding short-term risk, KNSA is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check ADMA's competition here
KNSA vs SWTX Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, KNSA is priced at $45.78, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas SWTX's P/E ratio is -13.78. In terms of profitability, KNSA's ROE is +0.11%, compared to SWTX's ROE of -0.45%. Regarding short-term risk, KNSA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check SWTX's competition here
KNSA vs CNTA Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, CNTA has a market cap of 3.5B. Regarding current trading prices, KNSA is priced at $45.78, while CNTA trades at $26.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas CNTA's P/E ratio is -13.93. In terms of profitability, KNSA's ROE is +0.11%, compared to CNTA's ROE of -0.68%. Regarding short-term risk, KNSA is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check CNTA's competition here
KNSA vs ACAD Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, ACAD has a market cap of 3.5B. Regarding current trading prices, KNSA is priced at $45.78, while ACAD trades at $20.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas ACAD's P/E ratio is 8.96. In terms of profitability, KNSA's ROE is +0.11%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, KNSA is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check ACAD's competition here
KNSA vs CORT Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, CORT has a market cap of 3.4B. Regarding current trading prices, KNSA is priced at $45.78, while CORT trades at $32.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas CORT's P/E ratio is 39.21. In terms of profitability, KNSA's ROE is +0.11%, compared to CORT's ROE of +0.15%. Regarding short-term risk, KNSA is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check CORT's competition here
KNSA vs NAMS Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, NAMS has a market cap of 3.3B. Regarding current trading prices, KNSA is priced at $45.78, while NAMS trades at $28.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas NAMS's P/E ratio is -16.64. In terms of profitability, KNSA's ROE is +0.11%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, KNSA is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check NAMS's competition here
KNSA vs DNLI Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, DNLI has a market cap of 3.3B. Regarding current trading prices, KNSA is priced at $45.78, while DNLI trades at $20.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas DNLI's P/E ratio is -6.93. In terms of profitability, KNSA's ROE is +0.11%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, KNSA is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check DNLI's competition here
KNSA vs LQDA Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, LQDA has a market cap of 3.2B. Regarding current trading prices, KNSA is priced at $45.78, while LQDA trades at $36.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas LQDA's P/E ratio is -25.11. In terms of profitability, KNSA's ROE is +0.11%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, KNSA is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check LQDA's competition here
KNSA vs EWTX Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, EWTX has a market cap of 3.2B. Regarding current trading prices, KNSA is priced at $45.78, while EWTX trades at $29.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas EWTX's P/E ratio is -18.15. In terms of profitability, KNSA's ROE is +0.11%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, KNSA is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check EWTX's competition here
KNSA vs GPCR Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, GPCR has a market cap of 3.1B. Regarding current trading prices, KNSA is priced at $45.78, while GPCR trades at $53.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas GPCR's P/E ratio is -22.40. In terms of profitability, KNSA's ROE is +0.11%, compared to GPCR's ROE of -0.15%. Regarding short-term risk, KNSA is less volatile compared to GPCR. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check GPCR's competition here
KNSA vs DYN Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, DYN has a market cap of 3B. Regarding current trading prices, KNSA is priced at $45.78, while DYN trades at $17.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas DYN's P/E ratio is -5.16. In terms of profitability, KNSA's ROE is +0.11%, compared to DYN's ROE of -0.61%. Regarding short-term risk, KNSA is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check DYN's competition here
KNSA vs IDYA Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, IDYA has a market cap of 2.9B. Regarding current trading prices, KNSA is priced at $45.78, while IDYA trades at $33.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas IDYA's P/E ratio is -25.85. In terms of profitability, KNSA's ROE is +0.11%, compared to IDYA's ROE of -0.11%. Regarding short-term risk, KNSA is less volatile compared to IDYA. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check IDYA's competition here
KNSA vs TARS Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, TARS has a market cap of 2.9B. Regarding current trading prices, KNSA is priced at $45.78, while TARS trades at $67.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas TARS's P/E ratio is -42.74. In terms of profitability, KNSA's ROE is +0.11%, compared to TARS's ROE of -0.20%. Regarding short-term risk, KNSA is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check TARS's competition here
KNSA vs MORF Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, KNSA is priced at $45.78, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas MORF's P/E ratio is -14.88. In terms of profitability, KNSA's ROE is +0.11%, compared to MORF's ROE of -0.29%. Regarding short-term risk, KNSA is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check MORF's competition here
KNSA vs MOR Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, KNSA is priced at $45.78, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas MOR's P/E ratio is -12.64. In terms of profitability, KNSA's ROE is +0.11%, compared to MOR's ROE of -1.84%. Regarding short-term risk, KNSA is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check MOR's competition here
KNSA vs CPRX Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, CPRX has a market cap of 2.9B. Regarding current trading prices, KNSA is priced at $45.78, while CPRX trades at $23.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas CPRX's P/E ratio is 13.83. In terms of profitability, KNSA's ROE is +0.11%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, KNSA is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check CPRX's competition here
KNSA vs VERA Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, VERA has a market cap of 2.9B. Regarding current trading prices, KNSA is priced at $45.78, while VERA trades at $39.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas VERA's P/E ratio is -8.58. In terms of profitability, KNSA's ROE is +0.11%, compared to VERA's ROE of -0.60%. Regarding short-term risk, KNSA is less volatile compared to VERA. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check VERA's competition here
KNSA vs ARQT Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, ARQT has a market cap of 2.8B. Regarding current trading prices, KNSA is priced at $45.78, while ARQT trades at $22.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas ARQT's P/E ratio is -175.00. In terms of profitability, KNSA's ROE is +0.11%, compared to ARQT's ROE of -0.10%. Regarding short-term risk, KNSA is less volatile compared to ARQT. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check ARQT's competition here
KNSA vs DNTH Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, DNTH has a market cap of 2.8B. Regarding current trading prices, KNSA is priced at $45.78, while DNTH trades at $77.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas DNTH's P/E ratio is -22.50. In terms of profitability, KNSA's ROE is +0.11%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, KNSA is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for KNSA.Check DNTH's competition here
KNSA vs KDNY Comparison March 2026
KNSA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 3.4B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, KNSA is priced at $45.78, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 61.04, whereas KDNY's P/E ratio is -12.47. In terms of profitability, KNSA's ROE is +0.11%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, KNSA is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for KNSA.Check KDNY's competition here